The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

NCT03667014 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis
Atopic Dermatitis Eczema

Interventions

DRUG: Dupilumab

Sponsor

University of California, San Francisco

Collaborators

[object Object]